Retrophin and St. Jude Children’s Research Hospital to Collaborate on Rare Disease Research Program
08:33 EDT 16 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Retrophin, LLC, a privately-held New York-based, biotechnology company
focused on discovering and developing treatments for rare and
life-threatening diseases, today announced that it has entered a
sponsored research agreement w...
Other Sources for this Article
Retrophin, LLC
Martin Shkreli, CEO, 212-983-1310
Martin.Shkreli@retrophin.com
or
6
Degrees
Tony Plohoros, 908-591-2839
tplohoros@6degreespr.com
or
St.
Jude
Judith Black, 901-595-2434
Judith.Black@stjude.org
More From BioPortfolio on "Retrophin and St. Jude Children’s Research Hospital to Collaborate on Rare Disease Research Program"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
